345 Park Avenue South

Mega Menu WP The Core Labs Behind the Deals - Image

Blue

News & Insights

Your Home in NYC

Cure Founders Pass Membership Benefits 03 Tab Bar Image

Dark Blue

Apply for Membership

Where Healthcare Innovators Connect

Magenta

Attend An Event

Accelerating Advances in Health

Green

About

Contact us

The Cure Editorial Team byline indicates that an article was produced in house. In some cases, multiple contributors shape and update a piece over time to ensure it reflects the most accurate, relevant, and rigorously vetted information for the biotech and healthcare community.

A survey of 303 US institutions reveals how access to foundational vs. frontier core labs shapes translational success.

CII White Paper - The Labs Behind the Deals Core Technologies - Image

Cure Original Report: The Core Labs Behind the Deals

The United States leads in scientific quality and commercial depth. China leads in speed, scale, and cost. Five analyses map both sides of the divide.

Thumbnail CII US v China 1200x675 - Image

Racing to Cures: The Cure U.S.-China Biotech Competitiveness Scorecard

A Q&A with the co-founder and CEO of Hi-Rx, a platform that connects pharmaceutical sponsors and clinical sites with on-demand nurses, on why clinical trial recruitment keeps breaking at the same point, and what a nurse network can do that a CRO can't.

Cure Member Spotlight: Russell Bar

A Q&A with the founder of Rhizome AI, on why regulatory affairs teams are still searching PDFs by hand, and what it will take to give them something better.

Cure Member Spotlight: Chetan Mishra

A Q&A with CEO of Genprex on the intravenous gene therapy platform behind Reqorsa, how the company is advancing pipelines in both lung cancer and diabetes, and what it still needs to prove.

Cure Member Spotlight: Ryan Confer

CII-Launch - Glossary - Image

Glossary

The data, the framework, and the decisions behind the first ranking of U.S. biomedical institutions on translational performance.

CII Prelaunch - Methodology How We Built the Cure Innovation Index - Image

Methodology How We Built the Cure Innovation Index - Image

Methodology: How We Built the Cure Innovation Index

As part of the Cure Innovation Index, we surveyed 3,395 U.S. biomedical researchers to understand why discoveries aren't consistently commercialized and what the highest-performing institutions do differently.

CII-launch - What Makes an Institution Innovative? - Image

What Makes an Institution Innovative? A Cure Original Report

A Q&A with Peter Farmakis, CEO of 32 Biosciences, on building a company around the biology most microbiome startups missed, and what it takes to move from academic science to a fundable, clinical-stage therapeutic.

Cure Member Spotlight: Peter Farmakis Image

Cure Member Spotlight: Peter Farmakis

A Q&A with Larry Raoul James, CEO and President of MindLab, on why the opioid crisis was a drug design problem, and what it takes to build a next-generation pain therapeutic in a challenging category.

Cure Member Spotlight: Larry Raoul James Image

Cure Member Spotlight: Larry Raoul James

A Q&A with Irene Rombel, Co-Founder and CEO of BioCurie, on why manufacturing—not discovery—is the real bottleneck in cell and gene therapy, and what it takes to build an AI-driven software company at the frontier of genomic medicine.

Cure Member Spotlight: Irene Rombel, PhD

A Q&A with Oriana Zinani, PhD, Co-Founder and CEO of Applied PharmacoDynamics, on the science behind APD’s lead program for cocaine use disorder and what it takes to advance a first-in-class therapy in an area with enormous unmet need.


Cure Member Spotlight: Oriana Zinani, PhD

A Q&A with Matt Lewis, CEO of Transformental, on why most AI transformations fail for human reasons, how healthcare organizations build “brain capital,” and what it takes to introduce AI responsibly in high-stakes environments.

Cure Member Spotlight: Matt Lewis Image

Cure Member Spotlight: Matt Lewis

Business coach Chris Westfall explains why founders should resist making a formal mentorship ask too soon, and how to test for alignment, invite candid feedback, and build a relationship that sharpens strategy over time.

The Smarter Way to Find a Mentor for Your Startup, According to a Business Coach

Nolan Townsend, CEO of Lexeo Therapeutics, shares candid lessons on how IPOs reshape investor relationships, disclosure strategy, and the day-to-day responsibilities of leading a public biotech company.

A Biotech CEO on How Going Public Reshapes the Role

Lessons from Wandercraft CEO Matthieu Masselin on how risk, reimbursement, and regulation fundamentally change when scaling a healthcare company across Europe and the US.

The Key Differences Between Building a Healthcare Company in the US vs Europe

A Q&A with Karolyn Chamberlin, COO of Rarecells, on the science behind ISET, why whole circulating tumor cells matter for early cancer detection, and the challenge of translating decades of academic research into clinical impact.

Cure Member Spotlight: Karolyn Chamberlin

Clare Peeters, CBO and CFO of The New York Academy of Sciences, shares why a small set of financial metrics should stay top of mind for healthcare founders.

3 Key Financial Metrics That Decide the Fate of Your Company

Meet the latest founders, investors, and operators joining the Cure community, spanning biotech, medtech, AI, and healthcare services.

Meet the Founders, Investors, and Operators Joining the Cure Community

In a Q&A with Cure, Excelsior's CEO Mike Foley explains why small-molecule chemistry has become a bottleneck, and how the company is rebuilding it for automation, AI, and domestic drug manufacturing.

thumbnail excelsior spotlight mike foley phd headshot image

“Chemistry Needs a Reset”: Inside Excelsior’s Plan to Rebuild Small-Molecule Discovery

Anne Fulenwider, co-founder and co-CEO of Alloy Helath, on why clear, jargon-free storytelling helps healthcare companies earn trust, traction, and scale. 

Storytelling Gives Healthcare Companies an Edge—Here's How to Use It Well Anne Fulenwider 16x9

Storytelling Gives Healthcare Companies an Edge—Here's How to Use It Well

Mathai Mammen, MD, Chairman, CEO, and President of Parabilis Medicines, shares how great biotech founders decide which diseases are worth pursuing, and why problem selection shapes everything that follows.

How Great Biotech Companies Decide Which Diseases to Take On

A Q&A with PolyCypher Health CEO Gilead Kedem, MD, on predicting chronic disease risk, rethinking polygenic scoring, and building preventive genomics for real-world care.

Cure Member Spotlight: Gilead Kedem, MD

A clear vision can set a biotech’s direction, but founders succeed when that vision adapts to new data, market shifts, and investor expectations. Greg Moss of Evommune explains why flexibility guides smarter strategy, stronger alignment, and better long term outcomes.

Why a Flexible Vision Is a Biotech Founder’s Strongest Asset

Unicycive Therapeutics CEO Shalabh Gupta shares how to learn the leadership mindset that will keep teams aligned, keep you steady under pressure, and help you turn setbacks into momentum.

How Leadership Shapes a Biotech Startup, and the Mindset That Drives Success

Biotech investor and Columbia Business School professor Dr. Aamir Rehman explains why the strongest early funding signal isn’t your science—it’s your founder’s equity. Here’s how it shapes investor trust.

The Funding Signal That Can Make or Break Your First VC Raise

Priyanka Jain, CEO and Co-Founder of Evvy, shares how cleanly dividing areas of ownership and expertise among the leadership team, and knowing exactly what not to build, helped the company move from idea to MVP, sell out its first product batch, and raise a $5M seed round.

The One Skill Early Founders Can’t Scale Without: Radical Ownership

Mark Michalski, MD, Chief Information Officer of Deerfield Management and CEO of Ascertain, a data innovation company, shares how AI is transforming diagnostics, life sciences, and healthcare operations, and why founders can’t afford to ignore it.

Why Every Healthcare Founder Needs an AI Strategy—Now 

Learn pitch-room dos and don’ts from David Greenwald, PhD of Deerfield Management—how to avoid unforced errors, structure your deck, sequence investor outreach, and follow up.

Cure’s Biotech Funding Tracker 2026

Cure Original Report: The Core Labs Behind the Deals

Your Home in NYC

Where Healthcare Innovators Connect

Accelerating Advances in Health

Cure Editorial Team

30 Articles by Cure Editorial Team